ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,701 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustrySchlierenBaxiva AG
Baxiva AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Baxiva AG develops glycoconjugate vaccines for the prevention of bacterial infections. Its platform chemically links serotype-specific bacterial polysaccharides to virus-like particles (VLPs) to generate immunogenic, multivalent vaccine candidates against Gram-negative pathogens such as Escherichia coli.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
3.7/5

Baxiva AG

✓ Offered2
Development of glycoconjugate vaccines
Development of vaccines against bacterial infections using serotype-specific polysaccharides from Gram-negative bacteria and proprietary chemical conjugation with virus-like particles.
Vaccine platform for multivalent bacterial target pathogens
Platform for the rapid development of highly multivalent vaccines against known and newly emerging bacterial pathogens, focusing on Gram-negative bacteria and resistance issues.
Trust & reputation

ranQ Trust Score of Baxiva AG: 3.7 out of 5.0

Trust Score3.7/ 5.0

Solid

x

Data basis 58% · As of October 2026

Baxiva AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Baxiva AG scores 53.4 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.25.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Baxiva AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Baxiva AG scores 32.2 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.34.34%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.30.04%
Qualifications+0.00

Baxiva AG reaches a ranQ Trust Score of 3.7 out of 5.0 — rated «Solid». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

February 23, 2026Media
Baxiva receives CHF 150,000 from Venture Kick to develop first-in-class Escherichia Coli vaccine
startupticker.ch
August 22, 2025Media
Baxiva secures $3 million to advance antibacterial vaccines
startupticker.ch

Knowledge

No knowledge articles yet

Once Baxiva AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Baxiva AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Baxiva AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Baxiva AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Südstrasse 1
8952 Schlieren

At a glance

Legal form
Corporation
UID
CHE-349.898.114
Founded
2025 · 1 year
Last commercial register change
February 19, 2026
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    LB
    LimmaTech Biologics AG
    Schlieren
    DP
    DISCO Pharmaceuticals Swiss GmbH
    Schlieren
    VA
    Virometix AG
    Schlieren
    RA
    Redbiotec AG
    Schlieren
    RI
    Repertoire Immune Medicines (Switzerland) AG
    Schlieren
    DG
    DeepVax GmbH
    Rämismühle
    EA
    Evax AG
    Zurich
    VA
    Vaccentis AG
    Zurich